MESS-study MRSA Eradication Study Skåne (MESS)

MESS- MRSA Eradication Study Skåne. A Comparison Between Systemic Antibiotic Treatment in Combination With Topical Mupirocintreatment With Only Topical Mupiroicintreatment to Eradicate MRSA in Throat Carriers

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

Study Overview

• Status: Completed
• Conditions: Throatcarriers of MRSA
• Intervention / Treatment: Drug: Mupirocin; Drug: Rifampin+Clindamycine or Trimehoprimsulfa

• Study Type: Interventional
• Enrollment (Actual): 69
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Stockholm, Sweden
    • Karolinska University Hospital
  • Örebro, Sweden
    • Örebro University Hospital
  • Skåne
    • Helsingborg, Skåne, Sweden
      • Helsingborg Hospital
    • Kristianstad, Skåne, Sweden
      • Kristianstad Hospital
    • Lund, Skåne, Sweden
      • Infectious department SUS Lund
    • Malmö, Skåne, Sweden
      • SUS Malmö

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 5 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion Criteria:

Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Mupirocin; Topical treatment	Drug: Mupirocin; Topical in the nose 3 times daily for 5 days; Drug: Rifampin+Clindamycine or Trimehoprimsulfa; Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
Active Comparator: Rifampicin+Clindamycine or Trimethoprimsulfa; Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2	Drug: Rifampin+Clindamycine or Trimehoprimsulfa; Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Culture for MRSA	after 6 months

Collaborators and Investigators

• Sponsor: Region Skane
• Investigators: Principal Investigator: Eva Melander, MD PHD, Labmedicin Skåne Malmö

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2011
• Primary Completion (Actual): May 1, 2015
• Study Completion (Actual): May 1, 2015

Study Registration Dates

• First Submitted: January 3, 2011
• First Submitted That Met QC Criteria: January 3, 2011
• First Posted (Estimate): January 4, 2011

Study Record Updates

• Last Update Posted (Actual): August 22, 2017
• Last Update Submitted That Met QC Criteria: August 21, 2017
• Last Verified: May 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-Bacterial Agents; Leprostatic Agents; Protein Synthesis Inhibitors; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 CYP3A Inducers; Antitubercular Agents; Antibiotics, Antitubercular; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C9 Inducers; Mupirocin; Rifampin
• Other Study ID Numbers: MRSA-2010; 2010-019727-55 (EudraCT Number)